Topical administration three times per week in alternate days to wild-type BALB/c mice of IMQ, a TLR7 agonist, successfully induced a lupus-like pathology in our animals not genetically prone to excessive TLR7 signaling [9]. The gene discussed is TLR7; the disease is systemic lupus erythematosus.